EFFECT OF DIETARY MODIFICATION ON BLOOD PRESSURE CONTROL

这项研究建议确定轻度高血压的最佳治疗方案 通过评估患者的生理和行为成分 从个人健康和公益的角度来看很重要，包括 血压变化、副作用、相关危险因素的变化，以及 心理和行为变量的变化。为了实现这一目标 目标，三种饮食成分(1-不改变饮食；2-减肥；3- 减少钠，增加钾)和三种药物方案(1- 安慰剂、2-噻嗪利尿剂和3-β受体阻滞剂)将进行评估 通过3x3析因设计。918(918)轻微至 中度未经治疗的高血压患者，年龄25至65岁，110至150岁 理想体重百分比，无主要终末器官损伤，且有坐姿 舒张压(DBP)在90-100之间将在三个月内登记 临床中心(艾伯特·爱因斯坦医学院，布朗克斯，纽约； 阿拉巴马大学伯明翰医学院；阿拉巴马大学伯明翰医学院 位于杰克逊的密西西比医疗中心)。协调中心将设在 位于休斯顿的德克萨斯大学公共健康学院。 生化和心理变量将在基线上确定，以及 每隔适当的时间。主要的结果变量将是血液 压力在六个月时发生变化。进一步的目标是确定 心血管风险以及心理功能和生活方式。在… 六个月，没有达到目标的人舒张期血液 压力治疗将使用抗高血压药物进行强化治疗。 所有患者将接受至少12个月和最多12个月的随访 总共三十个月。药物饮食治疗的远期疗效 除所述的主要评估外，还将评估模式 上面。 计划将占据前六个月，并在接下来的十八个月中进行入职 月份。过渡和淘汰将在第四年完成， 第四年的剩余时间将是分析和出版。

This study proposes to determine optimal management of mild hypertensive patients by evaluating physiological and behavioral components that are important from a personal health and public welfare viewpoint, including blood pressure change, side effects, change in associated risk factors, and change in psychological and behavioral variables. In order to achieve this goal, three dietary components (1 - no dietary change; 2 - weight loss; 3 - decreased sodium, increased potassium) and three drug regimens (1 - placebo, 2 - thiazide diuretic and 3 - beta blocker) will be evaluated through a 3 x 3 factorial design. Nine hundred and eighteen (918) mild to moderate untreated hypertensive individuals, age 25 to 65 years, 110-150 per cent ideal weight without major end-organ damage, and with sitting diastolic blood pressures (DBP) between 90-100 will be enrolled in three clinical centers (Albert Einstein College of Medicine, The Bronx, New York; University of Alabama at Birmingham Medical School; and the University of Mississippi Medical Center at Jackson). The Coordinating Center will be at the University of Texas School of Public Hedalth in Houston. Biochemical and psychological variables will be determined at baseline, and at appropriate intervals. The major outcome variable will be blood pressure change at six months. Further aims are to determine changes in cardiovascular risk and in psychological functioning and life style. At six months, individuals who have not reached their goal diastolic blood pressures will have a step-up therapy utilizing an antihypertensive drug. All patients will be followed for a minimum of twelve months and a maximum of thirty months in total. The long-term efficacy of drug diet treatment patterns will be assessed in addition to the primary evaluation described above. Planning will occupy the first six months and induction the next eighteen months. Transition and close-out will be completed during the fourth year, and the remainder of the fourth year will be analyses and publication.